Serum eosinophil cationic protein during treatment of asthma in children
Background: Serum eosinophil cationic protein (ECP) is suggested to reflect the degree of bronchial inflammation and hyperreactivity in patients with asthma. We measured serum ECP levels before and 1 and 5 months after treatment with inhaled budesonide ( n = 10) or sodium cromoglycate (SCG) ( n = 7)...
Gespeichert in:
Veröffentlicht in: | Journal of allergy and clinical immunology 1993-07, Vol.92 (1), p.34-38 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background:
Serum eosinophil cationic protein (ECP) is suggested to reflect the degree of bronchial inflammation and hyperreactivity in patients with asthma. We measured serum ECP levels before and 1 and 5 months after treatment with inhaled budesonide (
n = 10) or sodium cromoglycate (SCG) (
n = 7) in children with asthma.
Methods:
The daily dose of budesonide was 800 μg/m
2 during the first month and 400 μg/m
2 during the next 4 months. ECP levels were determined by radioimmunoassay.
Results:
ECP decreased during the 5 months of treatment (
p = 0.020 for treatment groups combined;
p = 0.049 for the budesonide group;
p = NS for the SCG group). The higher the serum ECP level at entry, the more it decreased during treatment, both in the budesonide group (r = −0.697,
p < 0.05) and in the SCG group (
r = −0.893, p < 0.05). No correlation was found between the ECP level and the ratio of forced expiratory volume in 1 second to forced vital capacity (FEV
1%) or between changes in these. However, basal pulmonary function was reduced in 8 of 16 subjects only, and FEV
1% did not change significantly in either group. Thus the absence of a correlation is understandable.
Conclusions:
The clinical value of the sensitive decrease in serum ECP remains to be established. |
---|---|
ISSN: | 0091-6749 1097-6825 |
DOI: | 10.1016/0091-6749(93)90034-D |